Clinical Trials

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

Are you in need of a heart or lung transplant or have you had one in the past 3 months? Have you undergone a lung or heart transplant in the past 3 months or are you a candidate for heart or lung transplant? Some people with advanced heart and lung disease have heart and lung transplants but these new organs are often rejected. When this happens, patients must have repeated biopsies, which are invasive and expensive. Researchers in this clinical study want to see if a blood test can predict organ rejection and take the place of biopsies. To participate, you must be 18 to 80 years old and be a candidate for heart or lung transplant or have had a heart or lung transplant no more than three months ago. The study is taking place in Bethesda, Maryland, at the NIH Clinical Center, as well as in Baltimore, Maryland, and Falls Church, Virginia.

This study is evaluating the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB.

Has your doctor recommended right heart cardiac catheterization for you? This study is investigating new magnetic resonance imaging (MRI) techniques that use a guidewire to help position a heart catheter within the heart. MRI fluoroscopy shows pictures of the heart so that doctors can watch while they work. Using the guidewire during MRI may improve the procedure of heart catheterization. To participate in this study, you must be at least 18 years old, and your doctor must have recommended right heart catheterization for you. This study is located in Bethesda, Maryland.

Are you an adult interested in a new treatment for pulmonary hypertension? This study is exploring whether a medicine called spironolactone can improve heart and lung function during exercise in people who have pulmonary hypertension. To participate in this study, you must be 18 to 99 years old and have a type of pulmonary hypertension known as pulmonary arterial hypertension. This study is located in Bethesda, Maryland.

Este estudio explora si un medicamento llamado espironolactona puede mejorar la función cardíaca y pulmonar durante el ejercicio en personas con hipertensión pulmonar. Para participar en este estudio, debe tener entre 18 y 99 años y un tipo de hipertensión pulmonar conocido como hipertensión arterial pulmonar. Este estudio se lleva a cabo en Bethesda (Maryland).